METHODS OF UPSCALING MESENCHYMAL STROMAL CELL PRODUCTION, COMPOSITIONS AND KIT THEREOF

• US 20160002601A1
• Filed: 01/14/2015
• Published: 01/07/2016
• Est. Priority Date: 03/03/2011
• Status: Abandoned Application

• Current Assignee: Stempeutics Research Pvt. Ltd.
• Original Assignee: Stempeutics Research Pvt. Ltd.
• Inventors: Raj, Swathi Sundar, Majumdar, Anish Sen, Kokundkar, Udaykumar, Balasubramanian, Sudha, Thej, Charan, Mruthynjaya, Ashwin Kunigal, Damodaran, Devi, Ramadasse, Balamurugan, Bhagwat, Swaroop
• Application Number:
  US14/597,135
• Publication Number:
  US 20160002601A1
• Time in Patent Office: Days
• US Class Current: 1/1
• CPC Class Codes: A01N 1/0221 Freeze-process protecting agents, i.e. substances protecting cells from effects of the physical process, e.g. cryoprotectants, osmolarity regulators like oncotic agents
• CPC Class Codes: C12N 2501/115 Basic fibroblast growth factor (bFGF, FGF-2)
• CPC Class Codes: C12N 2511/00 Cells for large scale production
• CPC Class Codes: C12N 5/0663 Bone marrow mesenchymal stem cells (BM-MSC)

Abstract

The present invention discloses a method of isolation, pooling and further culturing of Mesenchymal Stem cells (MSC) for clinical application. Present invention also discloses the method of establishing Master Cell bank, followed by Working Cell Bank from which the final therapeutic composition referred to as Investigational Product/Investigational Medicinal Product comprising of allogenic bone marrow-derived MSC is formulated for clinical applications. Present disclosure also discloses a robust manufacturing process for consistent production of clinical grade Mesenchymal Stromal cells (MSCs). The process enables production of highly viable potent cells. The process steps relating to preparation of media, cell seeding, harvesting are fine tuned to achieve consistency in cell yield, superior cell viability, purity, improved cell proliferation, high cell recovery, low HLA-DR expression, reduction in culture duration. The viability and purity of cells are further improved by optimized wash process without cell loss/cell stress. The disclosure further provides a method of cyrostoring MSCs at high cell density without affecting the viability of cells. It further provides economical means to store and transport at −80° C.

Claims

1. A process for culturing of mesenchymal stromal cells, said process comprising act of:

a) allowing the mesenchymal stromal cells cultured till a first predetermined passage, to expand to a second predetermined passage in presence of culture media comprising basic fibroblast growth factor (bFGF);

wherein said expansion is carried out by contacting the cells with said culture media when said cells achieve at least one pre-determined confluency; and

wherein the process increases number of the cells at the end of the second predetermined passage by 2000 folds when compared to number of the cells at the first predetermined passage.

2. The process as claimed in claim 1, wherein the increase in the number of cells occurs in a maximum period of 21 days.

3. The process as claimed in claim 1, wherein the cells at the first predetermined passage are allowed to expand to the second predetermined passage by consecutive passages;

and wherein the first predetermined passage ranges from passage 2 to passage 9; and

the second predetermined passage ranges from passage 5 to passage 10.

4. The process as claimed in claim 1, wherein the first predetermined passage is passage 3;

and the second predetermined passage is passage 5.

5. The process as claimed in claim 1, wherein number of the cells seeded for said expansion ranges from about 0.6 million to about 0.7 million cells;

and number of the cells obtained after said expansion is at least about 1800 million cells; and

wherein the process increases the number of cells by at least 2000 folds.

6. The process as claimed in claim 1, wherein components of the culture media are Dulbecco'"'"'s Modified Eagle Medium-KnockOut [DMEM-KO] at a concentration ranging from about 75% to 95%, Fetal Bovine Serum [FBS] at a concentration ranging from about 5% to 15%, Glutamine at a concentration ranging from about 0.5% to 2%, Pen-Strep having penicillin at a concentration of about 50 to about 100 U/ml and streptomycin at a concentration of about 50 to about 100 μ

g/ml, and basic Fibroblast Growth Factor (bFGF) at a concentration ranging from about 0.5 ng/ml to 5 ng/ml.

7. The process as claimed in claim 6, wherein the culture media is prepared by a process of master mixing of the components in a manner so as to avoid volumetric error and provide uniform distribution of the bFGF within multiple aliquots of the media, said process comprising acts of:

b) preparing ‘

X’

Ltrs of the culture media comprising the DMEM-KO, FBS, Glutamine and Pen-Strep, devoid of bFGF, and dispensing into ‘

X’

1Ltr containers and labelling the containers from 1 to ‘

X’

;

c) withdrawing ‘

Z’

ml of media from container No. 1, and dispensing into a new sterile container labelled No. ‘

X+1’

;

d) adding a predetermined quantity of bFGF to the ‘

X minus(−

) Z’

ml of media of container No. 1 and mixing well to obtain bFGF master mix;

e) separately withdrawing an equal quantity of media from each of the containers labelled 2 to ‘

X’ and

adding to the ‘

Z’

ml of media in container No. ‘

X+1’

, thereby making the total media volume of container No. ‘

X+1’

as ‘

B’

ml; and

f) separately withdrawing a second predetermined quantity of bFGF master mix obtained in step (c) and adding to each ‘

B’

ml media in containers 2 to ‘

X’

thereby making the volume in each of the said containers equal and preparing multiple aliquots of the culture media.

8. The process as claimed in claim 1, wherein the at least one pre-determined confluency is selected from ranges of confluencies comprising about 30% to about 40%;

about 40% to about 50%; and

about 60% to about 70%, or any combination thereof.

9. The process as claimed in claim 1, wherein the expansion by contacting the cells with the culture media comprises acts of:

a) expanding the cultured cells into a consecutive passage by seeding the cells at a seeding density ranging from about 1000 cell/cm² to about 7000 cells/cm² and providing the culture media to the seeded cells; and

b) allowing the cells to reach a predetermined confluency of about 40% to about 50%, and replacing the culture media to obtain the expanded cells;

wherein, the culture media employed throughout the expansion is at a concentration ranging from about 0.15 to about 0.35 ml/cm².

10. The process as claimed in claim 9, wherein the expansion increases the number of cells by at least 30 folds.

11. The process as claimed in claim 1, wherein the expansion by contacting the cells with the culture media comprises acts of:

a) expanding the cultured cells into a consecutive passage by seeding the cells at a seeding density ranging from about 1000 cell/cm² to about 7000 cells/cm² and providing the culture media to the seeded cells;

b) allowing the cells to reach a predetermined confluency of about 30% to about 40%, and adding the culture media to the cells without removing the spent media; and

c) allowing the cells to reach a second predetermined confluency of about 60% to about 70%, and replacing the culture media to obtain the expanded cells;

wherein, the culture media employed throughout the expansion is at a concentration ranging from about 0.15 to about 0.35 ml/cm².

12. The process as claimed in claim 11, wherein the expansion increases the number of cells by at least 40 folds.

13. The process as claimed in claim 1, wherein the expansion by contacting the cells with the culture media comprises acts of:

a) expanding the cultured cells into a consecutive passage by seeding the cells at a seeding density ranging from about 1000 cell/cm² to about 7000 cells/cm² and providing the culture media to the seeded cells;

b) allowing the cells to reach a predetermined confluency of about 40% to about 50%, and replacing the culture media of the cells;

c) further expanding the cells of step (b) into a second consecutive passage by seeding the cells at a seeding density ranging from about ranging from about 1000 cell/cm² to about 7000 cells/cm² and providing the culture media to the seeded cells;

d) allowing the cells to reach a predetermined confluency of about 30% to about 40%, and adding the culture media to the cells without removing the spent media; and

e) allowing the cells to reach a second predetermined confluency of about 60% to about 70%, and replacing the culture media to obtain the expanded cells;

wherein, the culture media employed throughout the expansion is at a concentration ranging from about 0.15 to about 0.35 ml/cm².

14. The process as claimed in claim 13, wherein the expansion increases the number of cells by at least 2000 folds.

15. The process as claimed in claim 1, wherein the cells obtained after said culturing are subjected to freezing with a freezing mixture at cell density ranging from about 5 million cells to about 25 million cells per ml of the freezing mixture.

16. The process as claimed in claim 15, wherein the freezing is carried out at a temperature ranging from about −

75 degrees Celsius to about −

85 degrees Celsius or at a temperature ranging from about −

190 degrees Celsius to about −

200 degrees Celsius; and

wherein the freezing mixture comprises a cryopreservant at a concentration ranging from about 2% to about 15%, preferably about 5%; and

wherein the cryopreservant is preferably DMSO.

17. The process as claimed in claim 16, wherein the freezing at said cell density allows retention of viability and post-thaw functionality.

18. The process as claimed in claim 1, wherein said process comprises act of:

a) allowing the mesenchymal stromal cells cultured till passage 3, to expand to passage 5 in presence of culture media comprising basic fibroblast growth factor (bFGF);

wherein said expansion is carried out by contacting the cells with said culture media when said cells achieve at least one pre-determined confluency; and

wherein the process increases number of the cells at the end of passage 5 by at least 2000 folds when compared to number of the cells at the passage 3.

19. The process as claimed in claim 1, wherein the expansion by contacting the cells with the culture media comprises acts of:

a) expanding the cells cultured to passage 3 to expand into passage 4 by seeding the passage 3 cells at a seeding density ranging from about 1000 cell/cm² to about 7000 cells/cm² and providing the culture media to the seeded cells;

b) allowing the cells to reach a predetermined confluency of about 40% to about 50%, and replacing the culture media;

c) further expanding the cells obtained at the end of step (b) into passage 5 by seeding the cells at a seeding density ranging from about 1000 cell/cm² to about 7000 cells/cm² and providing the culture media to the seeded cells;

d) allowing the cells to reach a predetermined confluency of about 30% to about 40%, and adding the culture media without removing the spent media; and

e) allowing the cells to reach a second predetermined confluency of about 60% to about 70%, and replacing the culture media to obtain the expanded cells;

wherein, the culture media employed throughout the expansion is at a concentration ranging from about 0.15 to about 0.35 ml/cm².

20. The process as claimed in claim 1, wherein the cells obtained upon said culturing process are further subjected to a combination of centrifugation and wash process prior to being formulated into a predetermined dosage form for clinical or therapeutic application;

and wherein the said combination reduces the levels of bovine serum albumin [BSA] present to an amount of below 50 ng/ml for said predetermined dosage, wherein said BSA is provided to the cells during the culturing process by the FBS in the culture media.

29. The process as claimed in claim 24, wherein the mesenchymal stromal cells are obtained by culturing of said cells by process as claimed in claim 1.

21. A method of reducing amount of BSA to a level of below 50 ng/ml for a predetermined dosage formulated for clinical or therapeutic application, said dosage comprising mesenchymal stromal cells obtained by culturing of said cells, said method comprising act of subjecting the composition to a combination of centrifugation and washing with phosphate buffer saline to reduce the amount of said BSA.

22. The method as claimed in claim 21, wherein the BSA at an amount of above 50 ng/ml is provided to the cells during the culturing of said cells involving use of components of bovine origin;

and wherein the level of below 50 ng/ml is regardless of the number of the cells in the dosage.

23. The method as claimed in claim 21, wherein the method comprises acts of:

a) subjecting the cells to a first centrifugation at speed ranging from about 1200 rpm to about 1800 rpm for time period ranging from about 7 minutes to about 10 minutes;

b) subjecting the centrifuged cells to a first washing with about 20 ml DPBS for cell numbers in the range of about 0.6 million to about 6 million, and re-centrifuging the washed cells at speed ranging from about 1200 rpm to about 1800 rpm for time period of about 10 minutes;

c) subjecting the re-centrifuged cells to a second washing with about 7 to about 9 ml of DPBS for cell numbers in the range of about 600 to about 6 million, followed by optional pooling of the cell samples; and

d) re-centrifuging the washed cells from step (c) at speed ranging from about 1200 rpm to about 1800 rpm for time period ranging from about 5 minutes to about 7 minutes to obtain the cells having BSA at a level of below 50 ng/ml.

24. A process for storing mesenchymal stromal cells, said process comprising step of subjecting the cells to a freezing mixture at a cell density ranging from about 5 million cells to about 25 million cells per ml of the freezing mixture, and storing the cells at a temperature ranging from about −

75 degrees Celsius to about −

85 degrees Celsius or at a temperature ranging from about −

190 degrees Celsius to about −

200 degrees Celsius.

25. The process as claimed in claim 24, wherein the storing of mesenchymal stromal cells in a freezing mixture at a cell density ranging from about 5 million cells to about 25 million cells per ml of the freezing mixture, and at a temperature ranging from about −

75 degrees Celsius to about −

85 degrees Celsius, allows retention of viability and post-thaw functionality for a period of at least 1 week without liquid nitrogen.

26. The process as claimed in claim 24, wherein the storing of mesenchymal stromal cells in a freezing mixture at a cell density ranging from about 5 million cells to about 25 million cells per ml of the freezing mixture, and at a temperature ranging from about −

190 degrees Celsius to about −

200 degrees Celsius, allows retention of viability and post-thaw functionality for a period of at least 1 month.

27. The process as claimed in claim 24, wherein the freezing mixture comprises a cryopreservant at a concentration ranging from about 4% to about 11%, preferably about 5%;

and wherein the cryopreservant is preferably DMSO.

28. The process as claimed in claim 24, wherein the freezing at said cell density allows retention of viability and post-thaw functionality.

30. The process as claimed in claim 24, wherein the process eliminates reconstitution of the cells prior to administration for a therapeutic purpose to a subject in need thereof.